JPH05255367A - Production of cantharidin derivative composition and anti-viral agents containing it - Google Patents

Production of cantharidin derivative composition and anti-viral agents containing it

Info

Publication number
JPH05255367A
JPH05255367A JP4041868A JP4186892A JPH05255367A JP H05255367 A JPH05255367 A JP H05255367A JP 4041868 A JP4041868 A JP 4041868A JP 4186892 A JP4186892 A JP 4186892A JP H05255367 A JPH05255367 A JP H05255367A
Authority
JP
Japan
Prior art keywords
cantharidin
oil
derivative composition
weight
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP4041868A
Other languages
Japanese (ja)
Inventor
Jitsuei O
日衛 王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP4041868A priority Critical patent/JPH05255367A/en
Publication of JPH05255367A publication Critical patent/JPH05255367A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE: To obtain cantharidin derivative composition that have oil-solubility, dissolution stability, and superior therapeutic effect and useful for treating viral diseases, by thermal reacting cantharidin with fat and oil, fatty acid or the like.
CONSTITUTION: Cantharidin or its free acid is reacted thermally with fat and oil such as bean oil, fatty acid such as lauric acid and/or aliphatic alcohol such as octylalcohol at a temp. of 80-210°C to obtain the objective composition. Preferably, the composition is contained in an anti-viral agent by 0.00005-0.005 weight % in terms of cantharidin.
COPYRIGHT: (C)1993,JPO

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、油溶性を改善した新規
なカンタリジン誘導体組成物の製法に関する。
FIELD OF THE INVENTION The present invention relates to a method for producing a novel cantharidin derivative composition having improved oil solubility.

【0002】[0002]

【従来の技術】カンタリジンは、昆虫であるハンミョウ
に含まれ、該昆虫の乾燥粉末は生薬カンタリスとしてカ
ンタリス製剤原料に用いられてきた。例えば、カンタリ
ス粉末にみつろう、松脂、牛脂、テレピン油等を加えて
製剤した軟膏剤は発疱剤、皮膚刺激薬として中国漢方に
おいて古くから用いられている。
2. Description of the Related Art Cantharidin is contained in an insect, Hanmyo, and a dry powder of the insect has been used as a crude drug Cantharis as a raw material for Cantharis preparations. For example, an ointment prepared by adding beeswax, pine butter, beef tallow, turpentine oil and the like to Cantalis powder has been used as a blistering agent and skin stimulant in Chinese medicine for a long time.

【0003】近年になって、カンタリジンは下記式を有
する純品として単離され、種々の生理活性が明らかにな
り、抗ウイルス肝炎などのウイルス感染症に有効である
ことが報告されている。
In recent years, cantharidin has been isolated as a pure product having the following formula, various physiological activities have been revealed, and it has been reported that it is effective for viral infections such as antiviral hepatitis.

【0004】[0004]

【化1】 [Chemical 1]

【0005】[0005]

【発明が解決しようとする課題】カンタリジンは油溶性
であるが、医薬として各種製剤を製造するには、溶解度
と溶解安定性をより高めることが必要である。本発明の
目的は、カンタリジンより溶解度の高いカンタリジン誘
導体組成物を提供することである。
Although cantharidin is oil-soluble, it is necessary to further increase solubility and dissolution stability in order to produce various preparations as a medicine. An object of the present invention is to provide a cantharidin derivative composition having higher solubility than cantharidin.

【0006】[0006]

【課題を解決するための手段】本発明においては、カン
タリジンもしくはその遊離酸に油脂、脂肪酸及び/又は
脂肪族アルコールを加熱反応させることにより、前記式
のカンタリジンの酸無水物基が開環して生成したカルボ
キシル基及び/又は環中のエポキシ基に、油脂、脂肪酸
及び/又は脂肪族アルコールが反応してエステル化反
応、エーテル化反応及び又はエステル変換反応等の種々
の反応が起こり、これら反応生成物が混合された新規な
組成物が得られ、これにより溶解度及び薬効が改善され
ることが見い出された。
In the present invention, by heating and reacting cantharidin or its free acid with fats and oils, fatty acids and / or aliphatic alcohols, the acid anhydride group of cantharidin of the above formula is opened. The generated carboxyl group and / or epoxy group in the ring is reacted with fats and oils, fatty acids and / or aliphatic alcohols to cause various reactions such as esterification reaction, etherification reaction and / or ester conversion reaction. It has been found that a novel composition of matter is obtained, which improves solubility and efficacy.

【0007】本発明の方法における加熱反応は、常圧下
に撹拌して、80〜210℃で行われる。約105℃
で、カンタリジンは油脂等に急速に溶解し、さらに温度
を上げると溶解度は増すが、最高の温度範囲は102〜
110℃である。この温度範囲では、溶解及び反応は、
連続的に撹拌して30分以内に完結する。前記油脂等の
一部はカンタリジンもしくはその遊離酸と反応するが、
残部は生成したカンタリジン誘導体の溶媒になるので、
カンタリジン誘導体0.0001〜0.1重量%(カン
タリジン換算)、さらに前記油脂等に加えてハンミョウ
油0〜4重量%及び酸化防止剤0〜2重量%となるよう
添加して加熱反応させると、溶解度及び溶解後の安定性
がより改善されたカンタリジン誘導体組成物を得る。
The heating reaction in the method of the present invention is carried out at 80 to 210 ° C. with stirring under normal pressure. About 105 ℃
Then, cantharidin dissolves rapidly in fats and oils, and the solubility increases with increasing temperature, but the maximum temperature range is 102 ~.
It is 110 degreeC. In this temperature range, dissolution and reaction
Stir continuously to complete within 30 minutes. Although some of the above-mentioned fats and oils react with cantharidin or its free acid,
The rest will be the solvent for the cantharidin derivative produced, so
When the cantharidin derivative is 0.0001 to 0.1% by weight (in terms of cantharidin), and in addition to the above fats and oils, 0-4% by weight of hanmyo oil and 0 to 2% by weight of an antioxidant are added, and the mixture is heated and reacted. A cantharidin derivative composition having improved solubility and stability after dissolution is obtained.

【0008】油脂としては、例えば大豆油、トウモロコ
シ油、菜種油、ヒマワリ油、ゴマ油、カカオ脂、ミリス
チン、牛脂が用いられ、脂肪酸としては、例えばラウリ
ン酸、パルミチン酸、ステアリン酸、オレイン酸が用い
られる。脂肪族アルコールとしては、例えばオクチルア
ルコール、ノニルアルコール、プロピレングリコール、
グリセリン、ポリエチレングリコールが用いられる。
As the fats and oils, for example, soybean oil, corn oil, rapeseed oil, sunflower oil, sesame oil, cocoa butter, myristin and beef tallow are used, and as the fatty acids, for example, lauric acid, palmitic acid, stearic acid and oleic acid are used. . Examples of the aliphatic alcohol include octyl alcohol, nonyl alcohol, propylene glycol,
Glycerin and polyethylene glycol are used.

【0009】カンタリスから精製カンタリジンを得るに
は、カンタリス(ハンミョウ粉末)をアセトン、クロロ
ホルム、ジクロロメタン、トリクロロメタンのような有
機溶媒に浸して抽出する。残渣は乾燥してから、再び濃
塩酸アセトン溶液に浸して再抽出し、濃塩酸及び生成し
た無機相を分離する。両者の有機相から有機溶媒を回収
すると粗製のカタリジンとハンミョウ油の混合物が得ら
れる。これに石油エーテルを加えて、ハンミョウ油を抽
出する操作を繰り返し、アルコールで洗浄して、さらに
再結晶させて結晶カンタリジンを得る。
In order to obtain purified cantharidin from Cantharis, Cantharis (agar powder) is immersed in an organic solvent such as acetone, chloroform, dichloromethane or trichloromethane for extraction. The residue is dried and then re-extracted by immersing it in concentrated hydrochloric acid-acetone solution again to separate concentrated hydrochloric acid and the formed inorganic phase. Recovery of the organic solvent from both organic phases yields a crude mixture of catalidine and algal oil. Petroleum ether is added to this, and the operation of extracting Hanmyo oil is repeated, washed with alcohol, and recrystallized to obtain crystalline cantharidin.

【0010】この結晶カンタリジンもしくはその遊離酸
に前記のようにして油脂等を加熱反応させて得たカンタ
リジン誘導体組成物は、必要に応じて酸化防止剤、例え
ばレシチン、没食子酸エステル、ビタミンC、ビタンミ
ンE、BHT、BHAを加え、さらに各種製剤に応じて
種々のふ形剤を加えて、常法により軟膏剤、ローション
剤、錠剤、注射剤、坐剤、エアゾール剤等を製造する。
これらの製剤中のカンタリジン誘導体組成物の含有量
は、カンタリジン換算で0.00005〜0.005重
量%である。
The cantharidin derivative composition obtained by heating and reacting the above crystalline cantharidin or its free acid with fats and oils as described above is an antioxidant such as lecithin, gallic acid ester, vitamin C, and vitamin C, if necessary. E, BHT, and BHA are added, and further various types of ointments are added according to various preparations, and ointments, lotions, tablets, injections, suppositories, aerosols and the like are manufactured by a conventional method.
The content of the cantharidin derivative composition in these preparations is 0.00005 to 0.005% by weight in terms of cantharidin.

【0011】[0011]

【実施例】【Example】

実施例1 結晶カンタリジン0.1g に、大豆油250g とハンミ
ョウ油1g を加え、常圧下に加熱し、105℃となった
ときカンタリジンは溶解した。さらに210℃まで昇温
して30分加熱反応させた。得られたカンタリジン誘導
体と油脂との混合物は、そのまま製剤原料として用いる
ことができる。
Example 1 To 0.1 g of crystalline cantharidin, 250 g of soybean oil and 1 g of algal oil were added and heated under normal pressure. When the temperature reached 105 ° C., cantharidin was dissolved. Furthermore, the temperature was raised to 210 ° C. and a heating reaction was carried out for 30 minutes. The obtained mixture of cantharidin derivative and fats and oils can be used as it is as a drug substance.

【0012】試験例1 尖圭コンジロームの治療効果 次の組成のクリーム剤を用いて、尖圭コンジロームに対
する治療効果を試験した。 実施例1で得られたカンタリジン誘導体と 油脂及びハンミョウ油混合物 25g 乳化ろう(ステアリルアルコール90g + ラウリル硫酸ナトリウム10g +精製水4ml) 12g 精製水 10m
Test Example 1 Therapeutic Effect of Condyloma acuminata The therapeutic effect on Condyloma acuminata was tested using a cream having the following composition. Cantharidin derivative obtained in Example 1 and mixture of fats and oils and alum oil 25 g Emulsified wax (stearyl alcohol 90 g + sodium lauryl sulfate 10 g + purified water 4 ml) 12 g purified water 10 m
l

【0013】男性包皮繋帯に紅色の米粒状の突出性いぼ
6個が発生した尖圭コンジローム患者の発病部位周辺
に、毎日クリーム剤を塗布した。1日目に1個が消失し
他も白く変り、3日目にすべてのいぼが消失又は縮小
し、5日目には正常に回復した。
[0013] A cream was applied daily around the affected area of a patient with Condyloma acuminata who had six red-colored rice grain-like protruding warts on the male foreskin tether. On the first day one disappeared and the others turned white, on the third day all the warts disappeared or shrank, and on the fifth day they recovered normally.

【0014】試験例2 ウイルス肝炎に対する治療効果 次の組成の静脈用注射液を用いて急性B型ウイルス肝炎
に対する治療効果を試験した。実施例1で得られたカン
タリジン誘導体と 油脂及びハンミョウ油混合物 10g 乳化剤(レシチン) 0.7g 精製水 100ml
Test Example 2 Therapeutic effect against viral hepatitis The therapeutic effect against acute hepatitis B viral hepatitis was tested using an intravenous injection solution having the following composition. Cantharidin derivative obtained in Example 1 and mixture of fat and oil and erythroid oil 10 g Emulsifier (lecithin) 0.7 g Purified water 100 ml

【0015】患者は治療前いずれもGPTが低く、極度
の黄疸症状を示した。1日2回3mlを静脈注射し、4週
後の治療効果は表1のとおりである。
Prior to treatment, the patient had a low GPT and exhibited severe jaundice. Table 1 shows the therapeutic effects after 4 weeks of intravenous injection of 3 ml twice a day.

【0016】[0016]

【表1】 [Table 1]

【0017】[0017]

【発明の効果】本発明の方法によって製造されたカンタ
リジン誘導体組成物は、油脂に対する溶解性が増し、か
つ溶解度の安定性が向上したため、ウイルス疾患に対す
る治療効果が改善された。
INDUSTRIAL APPLICABILITY The cantharidin derivative composition produced by the method of the present invention has improved solubility in oils and fats and improved stability of solubility, so that the therapeutic effect on viral diseases is improved.

Claims (10)

【特許請求の範囲】[Claims] 【請求項1】 カンタリジンもしくはその遊離酸に油
脂、脂肪酸及び/又は脂肪族アルコールを加熱反応させ
ることを特徴とするカンタリジン誘導体組成物の製造
法。
1. A process for producing a cantharidin derivative composition, which comprises reacting cantharidin or its free acid with an oil, a fatty acid and / or an aliphatic alcohol by heating.
【請求項2】 加熱反応を、前記油脂等にハンミョウ油
を添加して行う請求項1の製造法。
2. The production method according to claim 1, wherein the heating reaction is carried out by adding ruminal oil to the oil or fat.
【請求項3】 加熱反応を、酸化防止剤の存在下で行う
請求項1又は2記載の製造法。
3. The method according to claim 1, wherein the heating reaction is carried out in the presence of an antioxidant.
【請求項4】 加熱反応を、80〜210℃で行う請求
項1〜3項のいずれか1項に記載の製造法。
4. The method according to claim 1, wherein the heating reaction is carried out at 80 to 210 ° C.
【請求項5】 加熱反応を、102〜110℃で行う請
求項4記載の製造法。
5. The method according to claim 4, wherein the heating reaction is performed at 102 to 110 ° C.
【請求項6】 カンタリジンもしくはその遊離酸に、油
脂、脂肪酸及び/又は脂肪アルコールを加熱反応させて
得られるカンタリジン誘導体組成物を含むことを特徴と
する抗ウイルス剤。
6. An antiviral agent comprising a cantharidin derivative composition obtained by reacting cantharidin or its free acid with an oil, a fatty acid and / or a fatty alcohol by heating.
【請求項7】 カンタリジン誘導体組成物の含量が、カ
ンタリジン換算で、0.00005〜0.005重量%
である請求項6記載の抗ウイルス剤。
7. The content of the cantharidin derivative composition in terms of cantharidin is 0.00005 to 0.005% by weight.
The antiviral agent according to claim 6.
【請求項8】 油脂、脂肪酸及び/又は脂肪族アルコー
ル中に、カンタリジン誘導体0.0001〜0.1重量
%(カンタリジン換算)、ハンミョウ油0〜4重量%及
び酸化防止剤0〜2重量%を含むカンタリジン誘導体組
成物を含む請求項6又は7記載の抗ウイルス剤。
8. A cantharidin derivative in an amount of 0.0001 to 0.1% by weight (in terms of cantharidin), 0 to 4% by weight of kansai oil and 0 to 2% by weight of an antioxidant in an oil, a fatty acid and / or an aliphatic alcohol. The antiviral agent according to claim 6 or 7, which comprises a cantharidin derivative composition containing the same.
【請求項9】 抗肝炎ウイルス剤である請求項6〜8の
いずれか1項に記載の抗ウイルス剤。
9. The antiviral agent according to claim 6, which is an antihepatitis viral agent.
【請求項10】 抗コンジローム剤である請求項6〜8
のいずれか1項に記載の抗ウイルス剤。
10. An anti-condyloma drug as claimed in claim 6.
The antiviral agent according to any one of 1.
JP4041868A 1992-02-28 1992-02-28 Production of cantharidin derivative composition and anti-viral agents containing it Pending JPH05255367A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP4041868A JPH05255367A (en) 1992-02-28 1992-02-28 Production of cantharidin derivative composition and anti-viral agents containing it

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4041868A JPH05255367A (en) 1992-02-28 1992-02-28 Production of cantharidin derivative composition and anti-viral agents containing it

Publications (1)

Publication Number Publication Date
JPH05255367A true JPH05255367A (en) 1993-10-05

Family

ID=12620242

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4041868A Pending JPH05255367A (en) 1992-02-28 1992-02-28 Production of cantharidin derivative composition and anti-viral agents containing it

Country Status (1)

Country Link
JP (1) JPH05255367A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1454624A1 (en) * 2001-11-23 2004-09-08 Wei Wang Antiviral, antibacterial pharmaceutical composition of cantharidic anhydride and method of preparation thereof
JP2008528482A (en) * 2005-01-20 2008-07-31 クワン・ドン・ファーマシューティカル・カンパニー・リミテッド Composition for improving hair growth comprising a non-polar solvent soluble extract of Cantalis as an active ingredient
CN105028410A (en) * 2015-06-23 2015-11-11 潍坊友容实业有限公司 Attractant for xylotrechus and slug moths and using method of attractant
JP2018500336A (en) * 2014-12-17 2018-01-11 ヴェリカ ファーマシューティカルズ, インコーポレイテッドVerrica Pharmaceuticals, Inc. Commercially feasible synthesis of cantharidin and bioactive cantharidin derivatives
US11052064B2 (en) 2013-08-21 2021-07-06 Verrica Pharmaceuticals Inc. Compositions, methods and systems for the treatment of cutaneous disorders
US11147790B2 (en) 2017-06-06 2021-10-19 Verrica Pharmaceuticals Inc. Treatment of cutaneous disorders

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1454624A1 (en) * 2001-11-23 2004-09-08 Wei Wang Antiviral, antibacterial pharmaceutical composition of cantharidic anhydride and method of preparation thereof
EP1454624A4 (en) * 2001-11-23 2006-05-31 Wei Wang Antiviral, antibacterial pharmaceutical composition of cantharidic anhydride and method of preparation thereof
JP2008528482A (en) * 2005-01-20 2008-07-31 クワン・ドン・ファーマシューティカル・カンパニー・リミテッド Composition for improving hair growth comprising a non-polar solvent soluble extract of Cantalis as an active ingredient
US11052064B2 (en) 2013-08-21 2021-07-06 Verrica Pharmaceuticals Inc. Compositions, methods and systems for the treatment of cutaneous disorders
JP2018500336A (en) * 2014-12-17 2018-01-11 ヴェリカ ファーマシューティカルズ, インコーポレイテッドVerrica Pharmaceuticals, Inc. Commercially feasible synthesis of cantharidin and bioactive cantharidin derivatives
JP2021073173A (en) * 2014-12-17 2021-05-13 ヴェリカ ファーマシューティカルズ, インコーポレイテッドVerrica Pharmaceuticals, Inc. Commercially feasible synthesis of cantharidin and bioactive cantharidin derivative
CN105028410A (en) * 2015-06-23 2015-11-11 潍坊友容实业有限公司 Attractant for xylotrechus and slug moths and using method of attractant
US11147790B2 (en) 2017-06-06 2021-10-19 Verrica Pharmaceuticals Inc. Treatment of cutaneous disorders

Similar Documents

Publication Publication Date Title
EP0304603B1 (en) Polyunsaturated acids having vasokinetic action and pharmaceutical and cosmetic formulations containing them
DE69837623T2 (en) STEROLESTER AS FOOD ADDITIVE
EP3294850B1 (en) Very long chain polyunsaturated fatty acids from natural oils
EP0839897B1 (en) Method for producing conjugated linoleic acid
JPH0159318B2 (en)
WO2006079534A1 (en) Method for producing a dha-containing fatty acid composition
HU198171B (en) Process for concentrating delta 6 polyinsaturated fatty acids in the mixture of polyinsaturated fatty acids
WO2001018161A2 (en) Process for the preparation of conjugated linoleic acid (cla)
US3102114A (en) Polyoxyethylene derivatives of esters of sucrose with long-chain fatty acids
JP2003509506A (en) Method for extracting avocado furan lipid compounds and polyhydroxylated fatty alcohols, compositions based on the compounds and their use in therapy, beauty and food
IE64947B1 (en) A process for the continuous fractionation of a mixture of fatty acids
FR2706478A1 (en) Compositions of phenolic derivatives, their preparation and their applications as antioxidants.
JPH042575B2 (en)
JPH05255367A (en) Production of cantharidin derivative composition and anti-viral agents containing it
DE1692126A1 (en) Process for stabilizing food and feedstuffs that are sensitive to oxidation
US3249600A (en) Process for the preparation of purified sucrose esters and products obtained thereby
US2347460A (en) Process for treating fat-soluble vitamin-containing oils
DE2659048A1 (en) Inositol phosphatide ester derivs. - with antilipaemic, anti-atherosclerotic, platelet aggregation reducing and peripheral blood flow increasing activity
JP4393640B2 (en) Production of plant sterols
US3558679A (en) Process for the extraction of the unsaponifiable fraction of vegetable oils
DE3612861A1 (en) 1-HYDROXY-8-ACYLOXY-10-ACYLANTHRONE, METHOD FOR THE PRODUCTION THEREOF, AND COSMETIC AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS
KR100232483B1 (en) The edible oil and preparation thereof
EP0065390A1 (en) Purification of sucrose esters
DE4231636A1 (en) New anthrone and anthracene derivatives substituted in the 10-position, processes for their preparation, pharmaceutical or cosmetic compositions containing these compounds and their use
JPH0667869B2 (en) Pharmaceutical composition for treating adrenoleukodystrophy